SN BioScience's Innovative SNB-101 Receives FDA's Orphan Drug Designation for Gastric Cancer Treatment SN BioScience's SNB-101, a groundbreaking nanoparticle anticancer drug, has received Orphan Drug Designation from the FDA for gastric cancer, offering hope to patients.

SN BioScience's Innovative SNB-101 Receives FDA's Orphan Drug Designation for Gastric Cancer Treatment #South_Korea #Seongnam #SN_BioScience #Orphan_Drug #Nano_Drug